UCB says launch of Vimpat is important milestone

UCB has stated the availability of Vimpat (lacosamide) is an important milestone for people suffering from epilepsy and the company.

The new antepileptic drug (AEDs), designed as an add-on therapy to manage partial-onset seizures in patients aged 17 and over ? should be available in some pharmacies by the first week of June.

Dr Kathleen Bos, vice-president of UCB’s medical affairs, explained the treatment has been examined in combination with a range of AEDs and other commonly used medications.

Throughout clinical trials, no significant pharmacokinetic drug interactions were observed, which demonstrates the importance of Vimpat, she added.

Vice-president and general manager Rich Denness noted the launch of the treatment is a significant step.

“Bringing Vimpat to … patients underscores UCB’s commitment to the epilepsy community and UCB’s leadership position in this disease state,” he commented.

Earlier this month, the Food and Drug Administration approved the company’s drug Cimzia.

It is the only PEGylated anti-tumour necrosis factor to aid moderately to severely active rheumatoid arthritis in adults.